|
 |
|
|||||||
|
|||||||||
Diabetes 51:2126-2134, 2002
© 2002 by the American Diabetes Association, Inc.
Immunological Characterization and Therapeutic Activity of an Altered-Peptide Ligand, NBI-6024, Based on the Immunodominant Type 1 Diabetes Autoantigen Insulin B-Chain (9–23) Peptide
1 Neurocrine Biosciences, Inc., San Diego, California
2 University of Colorado Health Sciences Center, Barbara Davis Center for Childhood Diabetes, Denver, Colorado
The nonobese diabetic (NOD) mouse is a good model for human type 1 diabetes, which is characterized by autoreactive T-cell-mediated destruction of insulin-producing islet ß-cells of the pancreas. The 9–23 amino acid region of the insulin B-chain [B(9–23)] is an immunodominant T-cell target antigen in the NOD mouse that plays a critical role in the disease process. By testing a series of B(9–23) peptide analogs with single or double alanine substitutions, we identified a set of altered peptide ligands (APLs) capable of inhibiting B(9–23)-induced proliferative responses of NOD pathogenic T-cell clones. These APLs were unable to induce proliferation of these clones. However, vaccinations with the APLs induced strong cellular responses, as measured by in vitro lymphocyte proliferation and Th2 cytokine production (i.e., interleukin [IL]-4 and IL-10, but not 
-interferon [IFN-]). These responses were cross-reactive with the native antigen, B(9–23), suggesting that the APL-induced Th2 responses may provide protection by controlling endogenous B(9–23)-specific Th1 (i.e., IFN--producing) pathogenic responses. One of these APLs that contained alanine substitutions at residues 16 and 19 (16Y
A, 19CA; NBI-6024) was further characterized for its therapeutic activity because it consistently induced T-cell responses (e.g., T-cell lines and clones) that were of the Th2 type and that were cross-reactive with B(9–23). Subcutaneous injections of NBI-6024 to NOD mice administered either before or after the onset of disease substantially delayed the onset and reduced the incidence of diabetes. This study is the first to report therapeutic activity of an APL derived from an islet ß-cell-specific antigen in type 1 diabetes.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Kobayashi, N. Abiru, T. Arakawa, K. Fukushima, H. Zhou, E. Kawasaki, H. Yamasaki, E. Liu, D. Miao, F. S. Wong, et al. Altered B:9 23 Insulin, When Administered Intranasally with Cholera Toxin Adjuvant, Suppresses the Expression of Insulin Autoantibodies and Prevents Diabetes J. Immunol., August 15, 2007; 179(4): 2082 - 2088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Levisetti, A. Suri, S. J. Petzold, and E. R. Unanue The Insulin-Specific T Cells of Nonobese Diabetic Mice Recognize a Weak MHC-Binding Segment in More Than One Form J. Immunol., May 15, 2007; 178(10): 6051 - 6057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M NAKAYAMA, N BABAYA, D MIAO, R GIANANI, E LIU, J.F ELLIOTT, and G.S EISENBARTH Long-Term Prevention of Diabetes and Marked Suppression of Insulin Autoantibodies and Insulitis in Mice Lacking Native Insulin B9-23 Sequence Ann. N.Y. Acad. Sci., October 1, 2006; 1079(1): 122 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kinnunen, W. W. Kwok, A. Narvanen, M. Rytkonen-Nissinen, A. Immonen, S. Saarelainen, A. Taivainen, and T. Virtanen Immunomodulatory potential of heteroclitic analogs of the dominant T-cell epitope of lipocalin allergen Bos d 2 on specific T cells Int. Immunol., December 1, 2005; 17(12): 1573 - 1581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Mukherjee, D. Wagar, T. A. Stephens, E. Lee-Chan, and B. Singh Identification of CD4+ T Cell-Specific Epitopes of Islet-Specific Glucose-6-Phosphatase Catalytic Subunit-Related Protein: A Novel {beta} Cell Autoantigen in Type 1 Diabetes J. Immunol., May 1, 2005; 174(9): 5306 - 5315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. NAKAYAMA, H. MORIYAMA, N. ABIRU, S. R. BABU, K. SIKORA, M. LI, D. MIAO, J. C. HUTTON, J. F. ELLIOTT, and G. S. EISENBARTH Establishment of Native Insulin-Negative NOD Mice and the Methodology to Distinguish Specific Insulin Knockout Genotypes and a B:16 Alanine Preproinsulin Transgene Ann. N.Y. Acad. Sci., December 1, 2004; 1037(1): 193 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. RAJASALU, C. BARTH, A. SPYRANTIS, I. DURINOVIC-BELLO, R. UIBO, R. SCHIRMBECK, B. O. BOEHM, and W. KARGES Experimental Autoimmune Diabetes: A New Tool to Study Mechanisms and Consequences of Insulin-Specific Autoimmunity Ann. N.Y. Acad. Sci., December 1, 2004; 1037(1): 208 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Eisenbarth and P. A. Gottlieb Autoimmune Polyendocrine Syndromes N. Engl. J. Med., May 13, 2004; 350(20): 2068 - 2079. [Full Text] [PDF]
|
|
|
|
|
|
K. Kelemen, P. A. Gottlieb, A. L. Putnam, H. W. Davidson, D. R. Wegmann, and J. C. Hutton HLA-DQ8-Associated T Cell Responses to the Diabetes Autoantigen Phogrin (IA-2{beta}) in Human Prediabetes J. Immunol., March 15, 2004; 172(6): 3955 - 3962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hartemann-Heurtier, L. T. Mars, N. Bercovici, S. Desbois, C. Cambouris, E. Piaggio, J. Zappulla, A. Saoudi, and R. S. Liblau An Altered Self-Peptide with Superagonist Activity Blocks a CD8-Mediated Mouse Model of Type 1 Diabetes J. Immunol., January 15, 2004; 172(2): 915 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. GEENEN and F. BRILOT Role of the Thymus in the Development of Tolerance and Autoimmunity towards the Neuroendocrine System Ann. N.Y. Acad. Sci., May 1, 2003; 992(1): 186 - 195. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |